US pharma major AbbVie saw its shares drop 4.5% to $218.04 by close of trading on Friday, despite reporting financial results for the third quarter ended September 30, 2025, that beat expectation.

The top 20 global biopharmaceutical companies saw their combined market capitalization rise 4% in the third quarter of 2025 ...

Merck & Co (NYSE: MRK) posted third-quarter 2025 revenue of $17.3 billion, up 4% year over year, while adjusted earnings rose ...

US biotech 4D Molecular Therapeutics (Nasdaq: FDMT) has granted Japan’s Otsuka Pharmaceutical (TYO: 4578) exclusive rights to ...

German family-owned pharma major Boehringer Ingelheim has licensed a pre-clinical program from Japan’s Kyowa Kirin to develop ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) has begun in-house manufacturing and clinical use of CAR-T cell ...

US anti-virals giant Gilead Sciences late yesterday announced its third quarter 2025 results of operations, reporting total ...

The US Health Resources and Services Administration (HRSA) has approved nine drugs for a pilot testing a new rebate model ...

Swiss pharma giant Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic ...

The Institute for Clinical and Economic Review (ICER) has updated its assessment of the value of Novo Nordisk’s (NOV: N) ...

US biotech Biogen (Nasdaq: BIIB) reported third-quarter 2025 revenue of $2.5 billion, up 3%, with GAAP diluted EPS of $3.17, ...

Austrian biotech VALANX Biotech has appointed Klaus Orlinger as chief scientific officer, reinforcing its leadership as the ...